laboratori corpor america hold
diagnost tool
lh deliv solid beat execut well across
divis buy rais pt
lh deliv strong beat guid rev our/street expect
driven improv organ growth fx ad bp revenue growth
expect add year lh winner tax reform pama
implement expect lh well posit execut reiter
lh one top pick come away call increment
posit growth prospect covanc diagnost segment
reiter buy rais pt adj ep
covanc women health drove beat adj ep
beat rev y/i beat us street
covanc y/i drove beat top labcorp
diagnost rev beat street miss
rev/req miss pama cut volum beat
 volum beat organ volum grew vs
step organ volum surg
lh see growth varieti test women health organ rev grew
y/i drove point revenue growth
ceo dave king indic lh involv extens consist
howev updat report obviou flag risk
howev contact open lh well think
likelihood contact aet could open includ lh net-net could
net winner given larger health plan aet view
covanc covanc rev y/i top street
fx ad y/i growth covanc backlog
lh expect convert
revenue net order increas q/q
net book-to-bil end lh track
deliv cost synergi year integr chiltern
guid lh rais revenue guid y/i despit
ep beat lh maintain adj ep guid guid
bake headwind adopt guid assum
growth lh diagnost
growth covanc led chiltern acquisit anniversari
mid- high-single-digit organ growth covanc
pama chanc tweak labcorp ceo dave king respons question
affirm view acla vs hh case acla compel
power case acla ask go back congress said
would provid market-bas price inclus larger pool lab king
hold optim rate could adjust year
believ stock price outcom like believ
may see relief form less draconian rate-set year
think may visibl within next month
model model comment next page
labcorp lead refer laboratori test compani
also oper covanc drug develop
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
model got overhaul restat rais full year revenu
reflect adopt restat result reduct
labcorp diagnost revenu reduct
increas drug develop revenu
increas result total net increas revenu
rais rev y/i beat
fx rais adj ep y/i mainli carri
forward beat rais rev rais adj
ep y/i
 lh invest deal expect pace newli
announc deal could continu similar rate wouldnt surpris
see lh execut larger number dx deal expect lh priorit
 integr come showcas growth
expect outweigh buyback lh repurchas stock
author lh invest
acquisit lh end billion debt hover
gross leverag ratio ebitda recal lh guidanc contempl free cash
flow billion unchang thu expect see acquisit not-too-
distant futur certainli
pama chanc tweak labcorp ceo dave king respons question
affirm view acla vs hh case acla compel
power case acla ask go back congress said
would provid market-bas price inclus larger pool lab king
hold optim rate could adjust year
believ stock price outcom like believ
may see relief form less draconian rate set year
think may visibl within next month
mr king response/stat call regard case
ive said along first time sue govern uphil
battl nevertheless merit convinc power case
congress wrote statut specif instruct secretari
someth someth market survey includ hospit
secretari wrote rule exclud hospit unit state
secretari didnt congress said legal believ mean rule
set asid seek relief seek chang
payment cut seek rule set asid secretari told
go back congress said
right case judg rule favor rule set asid
secretari restart process rulemak end rule carri
congression intent would impact reset
reduct come market assess lab industri
exactli congress ask secretari congress said secretari
get medicar market didnt say get medicar absolut lowest price everi
singl test seem secretari tri achiev
buy unchang target price april
diagnost tool
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price april
diagnost tool
laboratori corpor america hold
buy unchang target price april
diagnost tool
laboratori corpor america hold
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin april et
date time product april et
laboratori corpor america hold lh
pt use multipl adj ep estim
price target use multipl adj ep estim
risk achiev target price valuat
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
buy unchang target price april
diagnost tool
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
